Loading clinical trials...

To Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ganaxolone Added to Standard of Care in Refractory Status Epilepticus (RSE) | Clinical Trials | Clareo Health

WITHDRAWNPHASE3

To Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ganaxolone Added to Standard of Care in Refractory Status Epilepticus (RSE)

A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ganaxolone Added to Standard of Care in Refractory Status Epilepticus

NCT05814523•Marinus Pharmaceuticals

View on ClinicalTrials.gov

Summary

This is a multicenter, double-blind, randomized, placebo-controlled study that will evaluate the efficacy, safety, and tolerability of intravenous (IV) ganaxolone versus placebo co-administered with IV antiepileptic drug (AED) according to standard of care for the treatment of RSE. Approximately 70 participants will be randomized in a 1:1 ratio to receive ganaxolone IV solution or placebo IV solution along with standard of care (SOC) IV AED.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Participant, participant's parent, guardian, or LAR must provide signed informed consent/assent, and once capable (per institution guidelines), there must be documentation of consent/assent by the participant demonstrating they are willing and aware of the investigational nature of the study and related procedures. Where allowed by law, where the participant lacks the capacity to make informed decisions regarding his/her medical treatment options, the treating clinician may follow their deferred consenting practices. The clinician will make the final decision based on the best interests of the participant.
•2. Male or females 18 years of age and older at the time of the first dose of IP.
•3. SE warranting imminent progression of treatment meeting the following criteria:
•a) A diagnosis of SE, warranting imminent progression of treatment for seizure control, with or without prominent motor features based on clinical and EEG findings:
•i. Diagnosis is established by:
•* For SE with prominent motor features: Clinical and EEG seizure activity indicative of convulsive, myoclonic, or focal motor SE.
•* For SE without prominent motor features (nonconvulsive SE): Appropriate clinical features and an EEG indicative of non-convulsive status epilepticus (NCSE).
•ii. For any type of SE:
•* At least 6 minutes of cumulative seizure activity over a 30-minute period within the hour before IP initiation, AND Seizure activity during the 30 minutes immediately prior to IP initiation.
•4. Participants must have received a benzodiazepine and at least 1 of the following IV AEDs for treatment of the current episode of SE administered at an adequate dose and for a sufficient duration, in the judgement of the investigator, to demonstrate efficacy. The benzodiazepine and at least 1 of the IV AEDs must have been administered at a dose that would be expected to be effective for the termination of the current episode of SE.
+7 more criteria

Exclusion Criteria

•1. Life expectancy of less than 24 hours.
•2. Anoxic brain injury or an uncorrected, rapidly reversable metabolic condition as the primary cause of SE (eg, hypoglycemia \< 50 milligrams per deciliter \[mg/dL\] or hyperglycemia \> 400 mg/dL).
•3. Participants who have received high-dose IV anesthetics (eg, midazolam, propofol, thiopental, or pentobarbital) during the current episode of SE for more than 18 hours, or who continue to have clinical or electrographic evidence of persistent seizures while receiving high-dose IV anesthetics.
•4. Clinical condition or advance directive that would NOT permit admission to the ICU or use of IV anesthesia.
•5. Participants known or suspected to be pregnant
•6. Participants with known allergy or sensitivity to progesterone or allopregnanolone medications/supplements
•7. Receiving a concomitant IV product containing Captisol.
•8. Known or suspected hepatic insufficiency or hepatic failure leading to impaired synthetic liver function.
•9. Known or suspected stage 3B (moderate to severe; estimated glomerular filtration rate \[eGFR\] 44-30 milliliters per minute per 1.73-meter square \[mL/min/1.73m\^2\]), stage 4 (severe; eGFR 29-15 mL/min/1.73m\^2), or stage 5 (kidney failure; eGFR \< 15 mL/min/1.73m\^2 or dialysis) kidney disease.
•10. Use of an investigational product for which less than 30 days or 5 half-lives have elapsed from the final product administration. Participation in a non-interventional clinical study does not exclude eligibility.
+1 more criteria

Locations (52)

Medical University of Innsbruck

Innsbruck, Austria

Kepler University Hospital

Linz, Austria

Kepler Universitätsklinikum GmbH

Linz, Austria

Paracelsus Medical University Salzburg, Christian Doppler University Hospital, Department of Neurology

Salzburg, Austria

Medical University Vienna

Vienna, Austria

Hôpital Universitaire de Bruxelles - Hôpital Erasme

Brussels, Belgium

UZA University Hospital Antwerpen

Edegem, Belgium

University Hospitals Leuven

Leuven, Belgium

Dubrava University Hospital

Zagreb, Croatia

University Hospital Centre Zagreb

Zagreb, Croatia

Key Dates

Start Date

March 1, 2024

Primary Completion Date

August 1, 2024

Completion Date

August 1, 2024

Last Updated

May 14, 2024

Conditions

Refractory Status Epilepticus

Interventions

Ganaxolone

DRUG

Placebo

DRUG

Standard of care

DRUG

Application of tDCS Stimulation in Controlling Refractory Status Epilepticus

NCT06344338

Refractory Status Epilepticus

View study

NOT_YET_RECRUITINGPHASE3

Targeted Hypothermia Versus Targeted Normothermia After Convulsive Refractory Status Epilepticus

NCT07383779

Convulsive Refractory Status EpilepticusStatus Epilepticus

View study

NOT_YET_RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 14, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

To Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ganaxolone Added to Standard of Care in Refractory Status Epilepticus (RSE)

Inclusion Criteria

Exclusion Criteria

Application of tDCS Stimulation in Controlling Refractory Status Epilepticus

Targeted Hypothermia Versus Targeted Normothermia After Convulsive Refractory Status Epilepticus

COMparison Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE"

Multicenter Retrospective Study of Isoflurane in Refractory and Super-Refractory Status Epilepticus

Ketamine for the Treatment of Refractory Status Epilepticus

An Open Label, Expanded Access Protocol With SAGE-547 for Super-Refractory Status Epilepticus